Reviews: Current Perspectives Cardiovascular Complications of Cancer Therapy Diagnosis, Pathogenesis, and Management Edward T.H. Yeh, MD; Ann T. Tong, MD; Daniel J. Lenihan, MD; S. Wamique Yusuf, MD; Joseph Swafford, MD; Christopher Champion, MD; Jean-Bernard Durand, MD; Harry Gibbs, MD; Alireza Atef Zafarmand, MD; Michael S. Ewer, MD From the Department of Cardiology, The University of Texas M.D. Anderson Cancer Center, Houston, Tex. Correspondence to Edward T.H. Yeh, MD, Department of Cardiology, Unit 449, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4095. E-mail etyeh@mdanderson.org The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factors such as the molecular site of action, the immediate and cumulative dose, the method of administration, the presence of any underlying cardiac condition, and the demographics of the patient. Moreover, toxicity can be affected by current or previous treatment with other antineoplastic agents. Cardiotoxic effects can occur immediately during administration of the drug, or they may not manifest themselves until months or years after the patient has been treated. In this article we review commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity. Further research will be required to more accurately predict which patients are at risk for developing cardiotoxicity. In addition, management plans, as well as strategies to reduce cardiotoxicity, need to be developed. Circulation. 2004;109:3122-3131.) Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.